Amneal Pharmaceuticals Q4 Revenue Tops $814M, EBITDA Hits $175M
Amneal Pharmaceuticals reported Q4 revenue of $814.3M, an 11% increase year over year, beating consensus by $6.4M, and delivered adjusted EPS of $0.21 along with 13% higher adjusted EBITDA of $175M. The company forecasted 2026 sales of $3.05-$3.15B, adjusted earnings of $0.93-$1.03, and EBITDA of $720-$760M.
1. Q4 Financial Results
Amneal Pharmaceuticals reported fourth-quarter revenue of $814.32 million, an 11% year-over-year increase that surpassed the $807.89 million consensus. Adjusted earnings per share reached $0.21, topping the $0.18 estimate, while adjusted EBITDA rose 13% to $175 million.
2. Specialty Product Uptake
The company highlighted strong uptake of its specialty product CREXONT and noted a robust cadence of new approvals in its Affordable Medicines segment, contributing to continued top-line growth in both branded and generic portfolios.
3. Fiscal 2026 Guidance
For fiscal 2026, Amneal expects sales between $3.05 and $3.15 billion versus a $3.21 billion consensus, adjusted earnings of $0.93 to $1.03 per share compared to $0.94 estimates, EBITDA of $720 to $760 million, and operating cash flow of $325 to $375 million.
4. Technical and Analyst Outlook
Shares have climbed 16% over the past 12 months, trading below key moving averages with neutral RSI and bearish MACD signals. The stock carries a Buy consensus with an average price target of $11.83 and a Barclays overweight target of $15.